	US 12,257,341 B2
	Injectable composition containing prodrug of caspase inhibitors, and preparation method therefor
Sung Won Kim, Seoul (KR); Jae Uk Baek, Seoul (KR); Hyun Seo Park, Seoul (KR); Myung Won Jin, Seoul (KR); Jung Gyu Park, Seoul (KR); Bok Tae Kim, Seoul (KR); and Sei Hyun Choi, Seoul (KR)
Assigned to LG CHEM, LTD., Seoul (KR)
Appl. No. 17/614,881
Filed by LG CHEM, LTD., Seoul (KR)
PCT Filed May 29, 2020, PCT No. PCT/KR2020/006953 § 371(c)(1), (2) Date Nov. 29, 2021, PCT Pub. No. WO2020/242234, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 10-2019-0064304 (KR), filed on May 31, 2019.
Prior Publication US 2022/0226234 A1, Jul. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/19 (2006.01); A61K 31/4725 (2006.01); A61K 41/17 (2020.01)

CPC A61K 9/0019 (2013.01) [A61K 9/16 (2013.01); A61K 9/1647 (2013.01); A61K 9/1682 (2013.01); A61K 9/19 (2013.01); A61K 31/4725 (2013.01); A61K 41/17 (2020.01)]

30 Claims

1. A pharmaceutical composition for injection comprising a microsphere which comprises (2S,3S)-2-(fluoromethyl)-3-((R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamido)-5-oxotetrahydrofuran-2-yl acetate, or a pharmaceutically acceptable salt or isomer thereof as an active ingredient; and poly(lactide-co-glycolide) as a biocompatible polymer.